Relapsing Remitting Multiple Sclerosis [clinicaltrials_resource:cd225fa0e8b998392d936f7ef6286da4]
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS [clinicaltrials:NCT00202995]clinicaltrials:NCT00203047A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. [clinicaltrials:NCT00203073]A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis [clinicaltrials:NCT00203086]clinicaltrials:NCT00211887Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients [clinicaltrials:NCT00220493]A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis [clinicaltrials:NCT00242268]clinicaltrials:NCT00337779A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod [clinicaltrials:NCT00349193]clinicaltrials:NCT00367484BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis [clinicaltrials:NCT00382629]Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis [clinicaltrials:NCT00429442]clinicaltrials:NCT00451204Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? [clinicaltrials:NCT00534261]clinicaltrials:NCT00574041clinicaltrials:NCT00594087Atorvastatin in Relapsing-Remitting Multiple Sclerosis [clinicaltrials:NCT00616187]Flupirtine as Oral Treatment in Multiple Sclerosis [clinicaltrials:NCT00623415]Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis [clinicaltrials:NCT00645749]Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo [clinicaltrials:NCT00668343]An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients [clinicaltrials:NCT00745615]A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS [clinicaltrials:NCT00837785]A Study for Patients With Relapsing Remitting Multiple Sclerosis [clinicaltrials:NCT00869986]Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) [clinicaltrials:NCT00914758]Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms [clinicaltrials:NCT00919217]clinicaltrials:NCT00939549clinicaltrials:NCT00947752A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) [clinicaltrials:NCT01037907]clinicaltrials:NCT01058005A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo [clinicaltrials:NCT01067521]clinicaltrials:NCT01071083clinicaltrials:NCT01097668Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis [clinicaltrials:NCT01185821]clinicaltrials:NCT01225289Vitamin D Pilot Study in Patients With Multiple Sclerosis [clinicaltrials:NCT01257958]clinicaltrials:NCT01307332clinicaltrials:NCT01317004Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis [clinicaltrials:NCT01337427]Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient [clinicaltrials:NCT01407211]Impact of Vitamin A on Multiple Sclerosis (MS) [clinicaltrials:NCT01417273]
condition [clinicaltrials_vocabulary:condition]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Relapsing Remitting Multiple Sclerosis [clinicaltrials_resource:cd225fa0e8b998392d936f7ef6286da4]
Bio2RDF identifier
cd225fa0e8b998392d936f7ef6286da4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cd225fa0e8b998392d936f7ef6286da4
identifier
clinicaltrials_resource:cd225fa0e8b998392d936f7ef6286da4
title
Relapsing Remitting Multiple Sclerosis
@en
label
Relapsing Remitting Multiple S ...... 25fa0e8b998392d936f7ef6286da4]
@en